The terms, per the grant. On October 10, 2023, Lonza Walkersville was issued US11781113B2, covering end-to-end cell therapy automation. The CPC tags — C12N 5/0636 (T-cell culture), C12M 23/42, C12M 29/20, C12M 41/00 (bioprocessing apparatus) — describe automated manufacturing equipment and process, not a therapeutic construct.
Why manufacturing IP is its own asset class: autologous cell therapies are made one patient at a time, and the cost, complexity, and reliability of that manufacturing is the field's central economic constraint. Process automation that lowers cost-of-goods and improves consistency is a moat — and IP covering it is a licensable, picks-and-shovels asset distinct from any drug.
The structure point: manufacturing IP supports supply, service, and licensing deals rather than drug royalties. Its value scales with the volume of therapies produced across the field, insulated from any single program's clinical fate. For a model, that is a diversified, infrastructure-style value stream.
What the grant does not promise: a clinical outcome or a marketed therapy — it is not a drug. It is an exclusivity claim on a manufacturing process and apparatus, valuable to the extent the field adopts it.
The takeaway: when valuing cell-therapy economics, read the manufacturing and automation IP as a separate, infrastructure-grade layer. Lonza's October 2023 automation grant is a dated example of the process IP behind the field's cost structure.